Geron soars on Mayo Clinic results for imetelstat

Finally, there's some good clinical trial news for Geron: The company's telomerase inhibitor imetelstat caused four complete remissions and one partial remission in patients with myelofibrosis in an investigator-sponsored trial at the Mayo Clinic.